Success of OncoArendi Therapeutics in the Fast track – app. 10 M EUR granted

In May and July 2015 BMC supported OncoArendi Therapeutics in grant applications for 1/1.1.1/2015 (“Fast track”) program by The National Centre for Research and Development. Commission included description of the market and the profitability of the project implementation in the application concerning “Preclinical research and clinical trials of a first-in-class development candidate in therapy of asthma and inflammatory bowel disease”. The scope of work was expanded to include the novelty of the projects results for “Development of a first-in-class small molecule drug candidate for treatment of idiopathic pulmonary fibrosis through chitotriosidase inhibition”. Both applications were ranked high among others and recommended for financing in the amount of app. 10 M EUR.